IndulgeRx wins all-A WIPO patent review for three IRX FOODSCORE filings

IndulgeRx Brands said WIPO has published all three of its PCT patent applications covering the IRX FOODSCORE AI platform after each received an all-A international search report. The result gives the Utah nutrition-tech company a public IP milestone that could strengthen fundraising, partnerships and licensing talks.

Why it matters: - IndulgeRx now has public WIPO records backing three patent filings that all cleared the international search stage with only “A” references. - The result can strengthen the company’s intellectual property position as it seeks seed and Series A funding, strategic partnerships and licensing opportunities. - The company says the milestone de-risks the IP moat behind multiple planned business lines, including consumer apps, CPG licensing, retail, payer and provider use cases, pharmacists, sports performance, researchers and government agencies.

What happened: - WIPO published three Patent Cooperation Treaty applications covering the IRX FOODSCORE platform on July 23, 2026. - The filings cover the platform as a software product, a system and a business method. - Each application received an all-A International Search Report from the U.S. International Searching Authority. - The published application numbers are WO2026156106 A1 for IRX FS Software, WO2026156110 A1 for IRX FS Method and WO2026156104 A1 for IRX FS System.

The details: - The International Search Report found no “X” citations and no “Y” citations across the three applications. - The Written Opinions concluded that the claims were novel, inventive and industrially applicable. - The examiner found claims 1–15 met the patentability test in each case. - The examiner also concluded that combining the prior art would have been “impermissible hindsight.” - The examiner said any combination of existing technology would not add advantages over the application or would require complexity beyond ordinary skill. - One filing required a minor procedural claim-grouping clarification, and the company says that did not affect the all-A grades or novelty findings. - IndulgeRx said the filings carry a priority date of January 16, 2025. - The company said the record predates future copycats. - More information is available through WIPO PATENTSCOPE and the company’s sites: IndulgeRx, IRX FOODSCORE and Fight Back Foods.

Between the lines: - The company is positioning the WIPO outcome as independent validation from a government-backed process, not just an internal claim. - The all-A result is unusual enough that IndulgeRx is comparing the outcome to what larger tech and health companies face in patent review. - The public publication gives investors and partners a clearer look at what the company believes is defensible IP around its nutrition scoring platform.

What’s next: - IndulgeRx is preparing for seed and Series A discussions and for strategic partnership conversations. - The company is likely to use the published patent record as evidence of novelty and defensibility in commercial talks. - IRX FOODSCORE will continue to be marketed as a tool that turns an input question about food suitability into two scores: Relevant Nutrition Score and Relevant Risk Score. - The company said the platform evaluates a person’s health history, age, gender, medications and goals against ingredients, additives, preservatives and preparation methods.

The bottom line: - IndulgeRx has turned a patent process milestone into a business signal: three published WIPO applications, three all-A search reports and a cleaner path to pitch its nutrition AI platform to investors and partners.